{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:35:20Z","timestamp":1791920120817,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:00:00Z","timestamp":1503532800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s11064-017-2371-0","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T23:33:45Z","timestamp":1503531225000},"page":"3289-3295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5709-9940","authenticated-orcid":false,"given":"David S.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunden","family":"Jinsmaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehonatan","family":"Sharabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,24]]},"reference":[{"key":"2371_CR1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0006-8993(03)03354-7","volume":"989","author":"WJ Burke","year":"2003","unstructured":"Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson\u2019s disease pathogenesis. Brain Res 989:205\u2013213","journal-title":"Brain Res"},{"key":"2371_CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0006-8993(00)02309-X","volume":"868","author":"I Lamensdorf","year":"2000","unstructured":"Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, Kopin IJ (2000) 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 868:191\u2013201","journal-title":"Brain Res"},{"key":"2371_CR3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0161-813X(03)00090-1","volume":"25","author":"WJ Burke","year":"2004","unstructured":"Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, Lampe P, Kumar VB, Franko M, Williams EA, Zahm DS (2004) Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25:101\u2013115","journal-title":"Neurotoxicology"},{"key":"2371_CR4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pharmthera.2014.06.006","volume":"144","author":"DS Goldstein","year":"2014","unstructured":"Goldstein DS, Kopin IJ, Sharabi Y (2014) Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther 144:268\u2013282","journal-title":"Pharmacol Ther"},{"key":"2371_CR5","doi-asserted-by":"crossref","first-page":"e15251","DOI":"10.1371\/journal.pone.0015251","volume":"5","author":"WM Panneton","year":"2010","unstructured":"Panneton WM, Kumar VB, Gan Q, Burke WJ, Galvin JE (2010) The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS ONE 5:e15251","journal-title":"PLoS ONE"},{"key":"2371_CR6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1568007033482913","volume":"2","author":"WJ Burke","year":"2003","unstructured":"Burke WJ (2003) 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson\u2019s disease. Curr Drug Targets CNS Neurol Disord 2:143\u2013148","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"2371_CR7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C","volume":"55","author":"AH Stokes","year":"1999","unstructured":"Stokes AH, Hastings TG, Vrana KE (1999) Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55:659\u2013665","journal-title":"J Neurosci Res"},{"key":"2371_CR8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bbadis.2011.02.013","volume":"1812","author":"S Jana","year":"2011","unstructured":"Jana S, Sinha M, Chanda D, Roy T, Banerjee K, Munshi S, Patro BS, Chakrabarti S (2011) Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson\u2019s disease. Biochim Biophys Acta 1812:663\u2013673","journal-title":"Biochim Biophys Acta"},{"key":"2371_CR9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/carcin\/23.6.1071","volume":"23","author":"EL Cavalieri","year":"2002","unstructured":"Cavalieri EL, Li KM, Balu N, Saeed M, Devanesan P, Higginbotham S, Zhao J, Gross ML, Rogan EG (2002) Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 23:1071\u20131077","journal-title":"Carcinogenesis"},{"key":"2371_CR10","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0006-2952(02)01353-9","volume":"64","author":"F Marco De","year":"2002","unstructured":"De Marco F, Perluigi M, Marcante ML, Coccia R, Foppoli C, Blarzino C, Rosei MA (2002) Cytotoxicity of dopamine-derived tetrahydroisoquinolines on melanoma cells. Biochem Pharmacol 64:1503\u20131512","journal-title":"Biochem Pharmacol"},{"key":"2371_CR11","doi-asserted-by":"crossref","first-page":"15597","DOI":"10.1074\/jbc.M610893200","volume":"282","author":"M Bisaglia","year":"2007","unstructured":"Bisaglia M, Mammi S, Bubacco L (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282:15597\u201315605","journal-title":"J Biol Chem"},{"key":"2371_CR12","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.neuro.2009.07.006","volume":"30","author":"AJ Linsenbardt","year":"2009","unstructured":"Linsenbardt AJ, Wilken GH, Westfall TC, Macarthur H (2009) Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress. Neurotoxicology 30:1030\u20131035","journal-title":"Neurotoxicology"},{"key":"2371_CR13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0028-3908(91)90007-X","volume":"30","author":"B Fornstedt","year":"1991","unstructured":"Fornstedt B, Carlsson A (1991) Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig. Neuropharmacology 30:463\u2013468","journal-title":"Neuropharmacology"},{"key":"2371_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/exnr.1997.6662","volume":"148","author":"TJ Montine","year":"1997","unstructured":"Montine TJ, Picklo MJ, Amarnath V, Whetsell WO Jr, Graham DG (1997) Neurotoxicity of endogenous cysteinylcatechols. Exp Neurol 148:26\u201333","journal-title":"Exp Neurol"},{"key":"2371_CR15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1046\/j.1471-4159.2002.00808.x","volume":"81","author":"JP Spencer","year":"2002","unstructured":"Spencer JP, Whiteman M, Jenner P, Halliwell B (2002) 5-S-cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem 81:122\u2013129","journal-title":"J Neurochem"},{"key":"2371_CR16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/jpet.115.230201","volume":"356","author":"DS Goldstein","year":"2016","unstructured":"Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y (2016) Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells. J Pharmacol Exp Ther 356:484\u2013493","journal-title":"J Pharmacol Exp Ther"},{"key":"2371_CR17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0955-2863(02)00229-2","volume":"13","author":"KL Tuck","year":"2002","unstructured":"Tuck KL, Hayball PJ (2002) Major phenolic compounds in olive oil: metabolism and health effects. J Nutr Biochem 13:636\u2013644","journal-title":"J Nutr Biochem"},{"key":"2371_CR18","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s11064-016-1959-0","volume":"41","author":"DS Goldstein","year":"2016","unstructured":"Goldstein DS, Jinsmaa Y, Sullivan P, Kopin IJ, Sharabi Y (2016) 3,4-Dihydroxyphenylethanol (hydroxytyrosol) mitigates the increase in spontaneous oxidation of dopamine during monoamine oxidase inhibition in PC12 cells. Neurochem Res 41:2173\u20132178","journal-title":"Neurochem Res"},{"key":"2371_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/BF00500085","volume":"332","author":"G Laschinski","year":"1986","unstructured":"Laschinski G, Kittner B, Brautigam M (1986) Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivatives. Naunyn Schmiedebergs Arch Pharmacol 332:346\u2013350","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2371_CR20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10787-008-8029-4","volume":"16","author":"R Torre de la","year":"2008","unstructured":"de la Torre R (2008) Bioavailability of olive oil phenolic compounds in humans. Inflammopharmacology 16:245\u2013247","journal-title":"Inflammopharmacology"},{"key":"2371_CR21","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/mnfr.201200795","volume":"57","author":"M Bock de","year":"2013","unstructured":"de Bock M, Thorstensen EB, Derraik JG, Henderson HV, Hofman PL, Cutfield WS (2013) Human absorption and metabolism of oleuropein and hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract. Mol Nutr Food Res 57:2079\u20132085","journal-title":"Mol Nutr Food Res"},{"key":"2371_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2016.06.001","volume":"83","author":"SC Greene","year":"2016","unstructured":"Greene SC, Noonan PK, Sanabria C, Peacock WF (2016) Effervescent N-acetylcysteine tablets versus oral solution N-acetylcysteine in fasting healthy adults: an open-label, randomized, single-dose, crossover, relative bioavailability study. Curr Ther Res Clin Exp 83:1\u20137","journal-title":"Curr Ther Res Clin Exp"},{"key":"2371_CR23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.parkreldis.2015.02.020","volume":"21","author":"M Katz","year":"2015","unstructured":"Katz M, Won SJ, Park Y, Orr A, Jones DP, Swanson RA, Glass GA (2015) Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson\u2019s disease. Parkinsonism Relat Disord 21:500\u2013503","journal-title":"Parkinsonism Relat Disord"},{"key":"2371_CR24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","volume":"36","author":"MJ Holmay","year":"2013","unstructured":"Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, Oz G, Cloyd JC, Tuite PJ (2013) N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 36:103\u2013106","journal-title":"Clin Neuropharmacol"},{"key":"2371_CR25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainresbull.2015.02.007","volume":"113","author":"A Rahimmi","year":"2015","unstructured":"Rahimmi A, Khosrobakhsh F, Izadpanah E, Moloudi MR, Hassanzadeh K (2015) N-acetylcysteine prevents rotenone-induced Parkinson\u2019s disease in rat: An investigation into the interaction of parkin and Drp1 proteins. Brain Res Bull 113:34\u201340","journal-title":"Brain Res Bull"},{"key":"2371_CR26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1046\/j.1471-4159.2000.0741605.x","volume":"74","author":"R Soto-Otero","year":"2000","unstructured":"Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz-Patino AM, Labandeira-Garcia JL (2000) Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson\u2019s disease. J Neurochem 74:1605\u20131612","journal-title":"J Neurochem"},{"key":"2371_CR27","first-page":"48","volume":"53","author":"A Sharma","year":"2007","unstructured":"Sharma A, Kaur P, Kumar V, Gill KD (2007) Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine. Cell Mol Biol (Noisy-le-grand) 53:48\u201355","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"2371_CR28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.nut.2007.05.004","volume":"23","author":"CM Chen","year":"2007","unstructured":"Chen CM, Yin MC, Hsu CC, Liu TC (2007) Antioxidative and anti-inflammatory effects of four cysteine-containing agents in striatum of MPTP-treated mice. Nutrition 23:589\u2013597","journal-title":"Nutrition"},{"key":"2371_CR29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3940(85)90229-0","volume":"60","author":"TL Perry","year":"1985","unstructured":"Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, Wall RA (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett 60:109\u2013114","journal-title":"Neurosci Lett"},{"key":"2371_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neulet.2004.03.072","volume":"363","author":"SW Park","year":"2004","unstructured":"Park SW, Kim SH, Park KH, Kim SD, Kim JY, Baek SY, Chung BS, Kang CD (2004) Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson\u2019s disease. Neurosci Lett 363:243\u2013246","journal-title":"Neurosci Lett"},{"key":"2371_CR31","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neubiorev.2015.04.015","volume":"55","author":"Slattery J Deepmala","year":"2015","unstructured":"Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R (2015) Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev 55:294\u2013321","journal-title":"Neurosci Biobehav Rev"},{"key":"2371_CR32","doi-asserted-by":"crossref","first-page":"e0157602","DOI":"10.1371\/journal.pone.0157602","volume":"11","author":"DA Monti","year":"2016","unstructured":"Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Cai J, Wei X, Bazzan AJ, Zhong L, Bowen B, Intenzo CM, Iacovitti L, Newberg AB (2016) N-acetyl cysteine may support dopamine neurons in Parkinson\u2019s disease: preliminary clinical and cell line data. PLoS ONE 11:e0157602","journal-title":"PLoS ONE"},{"key":"2371_CR33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.parkreldis.2016.12.011","volume":"35","author":"DS Goldstein","year":"2017","unstructured":"Goldstein DS, Sullivan P, Holmes C, Mash DC, Kopin IJ, Sharabi Y (2017) Determinants of denervation-independent depletion of putamen dopamine in Parkinson\u2019s disease and multiple system atrophy. Parkinsonism Relat Disord 35:88\u201391","journal-title":"Parkinsonism Relat Disord"},{"key":"2371_CR34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2016.07.009","volume":"31","author":"DS Goldstein","year":"2016","unstructured":"Goldstein DS, Holmes C, Sullivan P, Jinsmaa Y, Kopin IJ, Sharabi Y (2016) Elevated cerebrospinal fluid ratios of cysteinyl-dopamine\/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies. Parkinsonism Relat Disord 31:79\u201386","journal-title":"Parkinsonism Relat Disord"},{"key":"2371_CR35","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/npp.2014.214","volume":"40","author":"JS Fowler","year":"2015","unstructured":"Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L (2015) Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology 40:650\u2013657","journal-title":"Neuropsychopharmacology"},{"key":"2371_CR36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jnc.13042","volume":"133","author":"DS Goldstein","year":"2015","unstructured":"Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Kopin IJ, Sharabi Y (2015) Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson\u2019s disease. J Neurochem 133:14\u201325","journal-title":"J Neurochem"},{"key":"2371_CR37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00401-010-0791-x","volume":"121","author":"M Garrido","year":"2011","unstructured":"Garrido M, Tereshchenko Y, Zhevtsova Z, Taschenberger G, Bahr M, Kugler S (2011) Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons. Acta Neuropathol 121:475\u2013485","journal-title":"Acta Neuropathol"},{"key":"2371_CR38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13311-015-0404-4","volume":"13","author":"RC Reyes","year":"2016","unstructured":"Reyes RC, Cittolin-Santos GF, Kim JE, Won SJ, Brennan-Minnella AM, Katz M, Glass GA, Swanson RA (2016) Neuronal glutathione content and antioxidant capacity can be normalized in situ by N-acetyl cysteine concentrations attained in human cerebrospinal fluid. Neurotherapeutics 13:217\u2013225","journal-title":"Neurotherapeutics"},{"key":"2371_CR39","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1021\/acs.analchem.5b04420","volume":"88","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Burbulla LF, Krainc D, Ischiropoulos H (2016) Detection of free and protein-bound ortho-quinones by near-infrared fluorescence. Anal Chem 88:2399\u20132405","journal-title":"Anal Chem"},{"key":"2371_CR40","doi-asserted-by":"crossref","first-page":"27660","DOI":"10.1074\/jbc.M115.686584","volume":"290","author":"C Follmer","year":"2015","unstructured":"Follmer C, Coelho-Cerqueira E, Yatabe-Franco DY, Araujo GD, Pinheiro AS, Domont GB, Eliezer D (2015) Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of alpha-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). J Biol Chem 290:27660\u201327679","journal-title":"J Biol Chem"},{"key":"2371_CR41","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 108:4194\u20134199","journal-title":"Proc Natl Acad Sci USA"},{"key":"2371_CR42","doi-asserted-by":"crossref","first-page":"40699","DOI":"10.1038\/srep40699","volume":"7","author":"N Plotegher","year":"2017","unstructured":"Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, Greggio E, Bisaglia M, Veronesi M, Girotto S, Dalla Serra M, Perego C, Casella L, Bubacco L (2017) DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci Rep 7:40699","journal-title":"Sci Rep"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-017-2371-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-017-2371-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-017-2371-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T05:42:12Z","timestamp":1508478132000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-017-2371-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,24]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2371"],"URL":"https:\/\/doi.org\/10.1007\/s11064-017-2371-0","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,24]]}}}